基于网络药理学的葱白提取物治疗 非酒精性脂肪性肝病的机制研究和 验证

Mechanism and verification of Allii Fistulost Bulbus extract against nonalcoholic fatty liver disease based on network pharmacology

[目的]应用网络药理学的研究方法分析葱白提取物治疗非酒精性脂肪性肝病(NAFLD)的潜在作用靶点,并通过小分子RNA干扰(RNAi)技术在NAFLD大鼠进行验证。[方法]通过中药系统药理学分析平台(TCMSP)检索葱白的有效成分及作用靶点,再利用GeneCards网络数据库搜索NAFLD关键靶点,运用Perl语言软件对数据进行预处理,再通过R语言软件、Cytoscape软件以及String网络数据平台进行数据分析及作图。最后以RNAi技术抑制过氧化物酶体增殖物受体γ(PPARG)辅助活化因子A(PPARGC1A)PPARGC1A的表达,在NAFLD模型大鼠中验证葱白提取物的疗效。[结果]通过网络药理学的方法得到两个化合物,即山奈酚(kaempferol)与儿茶素(catechin),具有潜在疗效,并得到关键作用靶点PPARGC1A和PPARG。动物实验结果证实,与模型组相比葱白提取物可以改善脂肪肝病变,同时上调PPARGC1A及PPARG的表达(P<0.01)。[结论]运用网络药理学的方法预测了葱白治疗NAFLD的关键靶分子,并进行动物实验验证了葱白提取物通过诱导PPARGC1A治疗NAFLD的可行性。

[Objective]To investigate the potential targets of Allii Fistulost Bulbus in treatment of NAFLD based on network pharmacology,and SiRNA technology was used for verification in NAFLD rats.[Methods]The Traditional Chinese Medicine System Platform(TCMSP)database was used to find out active components and potential targets of Allii Fistulost Bulbus.Then the potential target information of NAFLD was retrieved by Genecards databases.Perl language software was used for preprocessing,and the R language software,Cytoscape software and String network data platform were used data analysis and picture production.In the end,we used SiRNA technology to inhibit the expression of PPARGC1A in the NAFLD rats to verify the curative effect.[Results]Two active components of kaempferol and catechin were screened out,and 2 important targets for the treatment of NAFLD with PPARGC1A and PPARG were predicted.The results of animal experiments confirm that compare to the model group,Allii Fistulost Bulbus extract can relieve liver steatosis,and up-regulated the protein expression of PPARGC1A and PPARG(P<0.01).[Conclusion]This study systematically predicted the potential target of Allii Fistulost Bulbus against NAFLD by Network Pharmacology and verified the feasibility to treat NAFLD by inducing PPARGC1A in animal experiment.